Toshio Takagi

List of Publications by Year
in descending order

100	1,415	394421	434195
papers	citations	h-index	g-index

101	101	101	1797
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chronic Kidney Disease Due to Surgical Removal of Nephrons: Relative Rates of Progression and Survival. Journal of Urology, 2014, 192, 1057-1063.	0.4	119
2	Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment. Targeted Oncology, 2016, 11, 605-617.	3.6	66
3	Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 355.e21-355.e29.	1.6	64
4	Early unclamping might reduce the risk of renal artery pseudoaneurysm after robotâ€assisted laparoscopic partial nephrectomy. International Journal of Urology, 2015, 22, 1096-1102.	1.0	54
5	Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. Targeted Oncology, 2019, 14, 453-463.	3.6	53
6	Enhanced computed tomography after partial nephrectomy in early postoperative period to detect asymptomatic renal artery pseudoaneurysm. International Journal of Urology, 2014, 21, 880-885.	1.0	49
7	Poorly Functioning Kidneys Recover from Ischemia after Partial Nephrectomy as Well as Strongly Functioning Kidneys. Journal of Urology, 2014, 192, 665-670.	0.4	44
8	Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study. International Journal of Clinical Oncology, 2017, 22, 136-144.	2.2	42
9	Acquired cystic diseaseâ€associated renal cell carcinoma is the most common subtype in longâ€term dialyzed patients: Central pathology results according to the 2016 WHO classification in a multiâ€institutional study. Pathology International, 2018, 68, 543-549.	1.3	37
10	Renal sinus exposure as an independent factor predicting asymptomatic unruptured pseudoaneurysm formation detected in the early postoperative period after minimally invasive partial nephrectomy. International Journal of Urology, 2015, 22, 356-361.	1.0	33
11	Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: AÂPropensity Score Matching Study. Clinical Genitourinary Cancer, 2017, 15, 598-604.	1.9	27
12	Robotâ€assisted laparoscopic versus open partial nephrectomy in patients with chronic kidney disease: A propensity scoreâ€matched comparative analysis of surgical outcomes. International Journal of Urology, 2017, 24, 505-510.	1.0	24
13	Assessment of Surgical Outcomes of the Non-renorrhaphy Technique in Open Partial Nephrectomy forÂâ‰¥T1b Renal Tumors. Urology, 2015, 86, 529-533.	1.0	23
14	Impact of the Mayo Adhesive Probability Score on the Complexity of Robot-Assisted Partial Nephrectomy. Journal of Endourology, 2018, 32, 928-933.	2.1	23
15	Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). World Journal of Urology, 2020, 38, 151-158.	2.2	23
16	Effect of Systemic Inflammation on Survival in Patients With Metastatic Renal Cell Carcinoma Receiving Second-line Molecular-targeted Therapy. Clinical Genitourinary Cancer, 2017, 15, 495-501.	1.9	22
17	Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. Japanese Journal of Clinical Oncology, 2021, 51, 646-653.	1.3	22
18	Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 542.e1-542.e9.	1.6	21

#	Article	IF	Citations
19	Robotâ€assisted laparoscopic partial nephrectomy versus laparoscopic partial nephrectomy: A propensity scoreâ€matched comparative analysis of surgical outcomes and preserved renal parenchymal volume. International Journal of Urology, 2018, 25, 359-364.	1.0	21
20	Comparison of Surgical Outcomes Between Resection and Enucleation in Robot-Assisted Laparoscopic Partial Nephrectomy for Renal Tumors According to the Surface-Intermediate-Base Margin Score: A Propensity Score-Matched Study. Journal of Endourology, 2017, 31, 756-761.	2.1	20
21	Comparisons of surgical outcomes between transperitoneal and retroperitoneal approaches in robot-assisted laparoscopic partial nephrectomy for lateral renal tumors: a propensity score-matched comparative analysis. Journal of Robotic Surgery, 2021, 15, 99-104.	1.8	20
22	Negative impact of papillary histological subtype in patients with renal cell carcinoma extending into the inferior vena cava: Singleâ€center experience. International Journal of Urology, 2013, 20, 1072-1077.	1.0	19
23	Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population. International Journal of Clinical Oncology, 2015, 20, 1035-1041.	2.2	18
24	Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. International Journal of Clinical Oncology, 2016, 21, 126-132.	2.2	18
25	Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 526-532.	1.6	18
26	Therapeutic role of template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract. World Journal of Clinical Oncology, 2015, 6, 237.	2.3	18
27	Multicenter Validation of Surgeon Assessment of Renal Preservation in Comparison to Measurement With 3D Image Analysis. Urology, 2015, 86, 534-538.	1.0	17
28	A propensity score-matched comparison of surgical precision obtained by using volumetric analysis between robot-assisted laparoscopic and open partial nephrectomy for T1 renal cell carcinoma: a retrospective non-randomized observational study of initial outcomes. International Urology and Nephrology, 2016, 48, 1585-1591.	1.4	17
29	Analysis of Atrophy After Clamped Partial Nephrectomy and Potential Impact of Ischemia. Urology, 2015, 85, 1417-1423.	1.0	16
30	Early Postoperative Screening by Contrast-Enhanced CT and Prophylactic Embolization of Detected Pseudoaneurysms Prevents Delayed Hemorrhage after Partial Nephrectomy. Journal of Vascular and Interventional Radiology, 2015, 26, 950-957.	0.5	16
31	Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution. International Journal of Clinical Oncology, 2020, 25, 892-898.	2.2	16
32	Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 77.e17-77.e25.	1.6	16
33	Comparison of progression to end-stage renal disease requiring dialysis after partial or radical nephrectomy for renal cell carcinoma in patients with severe chronic kidney disease. International Urology and Nephrology, 2016, 48, 1421-1427.	1.4	15
34	Comparison of perioperative outcomes with or without renorrhaphy during open partial nephrectomy: A propensity score-matched analysis. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 467-474.	1.5	15
35	Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 515-520.	1.6	15
36	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 735.e9-735.e16.	1.6	15

#	Article	IF	Citations
37	Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma. Targeted Oncology, 2018, 13, 745-755.	3.6	14
38	Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2018, 48, 860-863.	1.3	14
39	Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy. Targeted Oncology, 2019, 14, 179-186.	3.6	14
40	Comparison of survival rates in stage 1 renal cell carcinoma between partial nephrectomy and radical nephrectomy patients according to age distribution: a propensity score matching study. BJU International, 2016, 117, E52-9.	2.5	13
41	Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy. International Journal of Clinical Oncology, 2018, 23, 539-546.	2.2	13
42	Peritumoral pseudocapsule status according to pathological characteristics from robotâ€assisted laparoscopic partial nephrectomy for localized renal cell carcinoma. International Journal of Urology, 2019, 26, 446-450.	1.0	13
43	Lower Incidence of Postoperative Acute Kidney Injury in Robot-Assisted Partial Nephrectomy Than in Open Partial Nephrectomy: A Propensity Score-Matched Study. Journal of Endourology, 2020, 34, 754-762.	2.1	13
44	The De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Prognosticator in Patients With End-stage Renal Diseaseâ€“associated Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 236-240.e1.	1.9	12
45	Comparison of postoperative recovery after robotâ€assisted partial nephrectomy of T1 renal tumors through retroperitoneal or transperitoneal approach: A Japanese single institutional analysis. International Journal of Urology, 2021, 28, 183-188.	1.0	12
46	Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy. International Journal of Clinical Oncology, 2018, 23, 559-567.	2.2	11
47	Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy. Japanese Journal of Clinical Oncology, 2019, 49, 576-580.	1.3	11
48	Possible abscopal effect in urothelial carcinoma of the upper urinary tract after treatment with immune checkpoint inhibitors. IJU Case Reports, 2020, 3, 25-27.	0.3	11
49	Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus. Japanese Journal of Clinical Oncology, 2021, 51, 819-825.	1.3	11
50	Comparison of Kidney Function in the Early Postoperative Period in Transperitoneal Robot-Assisted Laparoscopic Partial Nephrectomy Between Anterior and Posterior Renal Tumors: A Propensity Score-Matched Study. Journal of Endourology, 2018, 32, 111-115.	2.1	10
51	Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma. In Vivo, 2020, 34, 1541-1546.	1.3	10
52	Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy of a solitary kidney. International Journal of Clinical Oncology, 2020, 25, 1155-1162.	2.2	10
53	Comparison of Surgical Outcomes Between Enucleation and Standard Resection in Robot-Assisted Partial Nephrectomy for Completely Endophytic Renal Tumors Through a 1:1 Propensity Score-Matched Analysis. Journal of Endourology, 2021, 35, 1779-1784.	2.1	9
54	Prognosis and characteristics of renal cell carcinoma in hemodialysis patients: Bilateral occurrence does not influence cancerâ€specific survival. International Journal of Urology, 2011, 18, 806-812.	1.0	8

#	Article	IF	Citations
55	Better recovery of kidney function in patients with de novo chronic kidney disease after partial nephrectomy compared with those with preâ€existing chronic kidney disease. International Journal of Urology, 2014, 21, 613-616.	1.0	8
56	Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2017, 47, 226-232.	1.3	8
57	Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study. Pathology, 2021, 53, 720-727.	0.6	8
58	Predictive role of Î³-glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma. International Journal of Clinical Oncology, 2021, 26, 552-561.	2.2	7
59	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2021, 51, 1751-1756.	1.3	7
60	Detection of a peritumoral pseudocapsule in patients with renal cell carcinoma undergoing robot-assisted partial nephrectomy using enhanced MDCT. Scientific Reports, 2021, 11, 2245.	3.3	7
61	Assessment of Outcomes in Partial Nephrectomy Incorporating Detailed Functional Analysis. Urology, 2014, 84, 1128-1133.	1.0	6
62	Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Marker of Nivolumab Monotherapy for Previously Treated Metastatic Renal Cell Carcinoma. In Vivo, 2021, 35, 2855-2862.	1.3	6
63	Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study. Targeted Oncology, 2021, 16, 493-502.	3.6	6
64	Computed tomography imaging characteristics of clear cell papillary renal cell carcinoma. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 26-33.	1.5	6
65	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. Clinical Genitourinary Cancer, 2021, , .	1.9	6
66	Fat-poor angiomyolipoma with cyst-like changes mimicking a cystic renal cell carcinoma: a case report. World Journal of Surgical Oncology, 2015, 13, 251.	1.9	5
67	New Longitudinal Component of the RENAL Nephrometry Score for Predicting the Operative Complexity in Transperitoneal Robot-Assisted Partial Nephrectomy. Journal of Endourology, 2022, 36, 762-769.	2.1	5
68	Differences in Clinical and Pathological Features of Renal Cell Carcinoma Between Japanese Patients After Kidney Transplantation and Those on Hemodialysis. Therapeutic Apheresis and Dialysis, 2017, 21, 133-138.	0.9	4
69	Prognostic Impact of the Components of Progressive Disease on Survival After First-Line Tyrosine Kinase Inhibitor Therapy for Metastatic Renal Cell Carcinoma. Targeted Oncology, 2018, 13, 379-387.	3.6	4
70	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. Medical Oncology, 2019, 36, 35.	2.5	4
71	Efficacy of nivolumab versus molecularâ€targeted therapy as secondâ€line therapy for metastatic renal cell carcinoma: Realâ€world data from two Japanese institutions. International Journal of Urology, 2021, 28, 99-106.	1.0	4
72	Greater Renal Function Benefit from Enucleation Technique for More Complex Renal Tumors in Robot-Assisted Partial Nephrectomy. Journal of Endourology, 2021, 35, 1512-1519.	2.1	4

#	Article	IF	Citations
73	Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma. In Vivo, 2021, 35, 3585-3589.	1.3	4
74	Association between Ureteral Clamping Time and Acute Kidney Injury during Robot-Assisted Radical Cystectomy. Current Oncology, 2021, 28, 4986-4997.	2.2	4
75	Efficacy and feasibility of robot-assisted partial nephrectomy for octogenarians: comparison with younger counterparts. Journal of Robotic Surgery, 2022, 16, 1165-1173.	1.8	4
76	Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era. Targeted Oncology, 2022, 17, 307-319.	3.6	4
77	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria. Targeted Oncology, 2022, 17, 475-482.	3.6	4
78	Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. International Journal of Clinical Oncology, 2020, 25, 705-712.	2.2	3
79	Therapeutic benefit of lymphadenectomy for older patients with urothelial carcinoma of the upper urinary tract: a propensity score matching study. Japanese Journal of Clinical Oncology, 2021, 51, 802-809.	1.3	3
80	Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multiâ€institutional study. International Journal of Urology, 2021, 28, 1075-1076.	1.0	3
81	Surgical outcomes of robot-assisted laparoscopic partial nephrectomy for cystic renal cell carcinoma. Journal of Robotic Surgery, 2022, 16, 649-654.	1.8	3
82	Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. Clinical and Experimental Nephrology, 2021, 25, 674-682.	1.6	2
83	Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy. Japanese Journal of Clinical Oncology, 2021, 51, 1744-1750.	1.3	2
84	Validation of a Predictive Model for New Baseline Renal Function After Radical Nephrectomy or Robot-Assisted Partial Nephrectomy in Japanese Patients. Journal of Endourology, 2022, 36, 745-751.	2.1	2
85	Surgical outcomes for older patients with renal cell carcinoma and inferior vena cava thrombus. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 110.e11-110.e18.	1.6	2
86	C-reactive protein kinetics to predict recurrence of high-risk renal cell carcinoma after radical surgery. International Journal of Clinical Oncology, 2022, 27, 969-976.	2.2	2
87	Surgical and Oncologic Outcomes of Laparoscopic Radical Nephrectomy for Nonâ€Metastatic Renal Cancer in Longâ€Term Dialysis Patients. Therapeutic Apheresis and Dialysis, 2017, 21, 31-37.	0.9	1
88	A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma. IJU Case Reports, 2022, 5, 126-128.	0.3	1
89	Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Japanese Journal of Clinical Oncology, 0, , .	1.3	1
90	Editorial Comment. Urology, 2014, 84, 334.	1.0	0

#	Article	IF	Citations
91	Editorial Comment. Urology, 2014, 84, 332-333.	1.0	0
92	Editorial Comment to Practical exâ€vivo evaluation of application of surgical clips to sutures during reâ€approximation of renal tissue in partial nephrectomy. International Journal of Urology, 2016, 23, 960-961.	1.0	0
93	The safety and validity of surgical resection for hemodialysis-dependent patients with renal cell carcinomas involving the inferior vena cava. International Cancer Conference Journal, 2016, 5, 136-139.	0.5	0
94	Editorial Comment to Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using lowâ€dose methylprednisolone. IJU Case Reports, 2021, 4, 25-25.	0.3	0
95	Robot-Assisted Laparoscopic Partial Nephrectomy for Allograft Renal Cell Carcinoma: A Case Report. Transplantation Proceedings, 2021, 53, 1445-1449.	0.6	0
96	Comparison of surgical outcomes after robot-assisted laparoscopic partial nephrectomy between patients continuing and discontinuing aspirin therapy: a Japanese single-centre study. Japanese Journal of Clinical Oncology, 2022, , .	1.3	0
97	â€œThrombusâ€firstâ€•or â€œthrombusâ€lastâ€•approach for surgical management of renal cell carcinoma with inferior vena cava thrombus. International Journal of Urology, 2022, , .	1.0	0
98	Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2Âyears of follow-up. Japanese Journal of Clinical Oncology, 2022, , .	1.3	0
99	Perioperative outcomes following robot-assisted partial nephrectomy for renal cell carcinoma according to surgeon generation. BMC Surgery, 2022, 22, .	1.3	0
100	Editorial Comment from Dr Ishihara et al. to Nomogram for predicting survival of renal cell carcinoma with tumor thrombus based on perioperative clinicopathological factors from a Chinese highâ€volume center. International Journal of Urology, 2022, 29, 993-994.	1.0	0